Twist Bioscience CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Twist Bioscience reports a 19.3% revenue increase for Q2 2026, reaching $110.7 million, but net loss also widened to $44.0 million.
NASDAQ
Twist Bioscience Corporation reported a 16.9% increase in Q1 revenue to $103.7 million and a reduced net loss of $30.5 million, driven by strong growth in DNA synthesis and NGS applications.
NASDAQ
Twist Bioscience Corporation reported a 16.9% increase in first-quarter revenue to $103.7 million, driven by growth in NGS Applications and DNA Synthesis and Protein Solutions, while narrowing its net loss to $30.5 million.
NASDAQ
Twist Bioscience reported a net income of $20.4 million for the quarter ended June 30, 2025, driven by an 18% revenue increase and a significant gain from the sale of its DNA data storage business.
NASDAQ
10-Q: Twist Bioscience Reports Q2 2025 Results: Revenue Up 23% Driven by NGS Tools and Synthetic Genes
Twist Bioscience's Q2 2025 revenue increased by 23% year-over-year, driven by growth in NGS tools and synthetic genes, while net losses decreased.
NASDAQ
Twist Bioscience saw a 24% increase in revenue and improved gross margins in the first quarter of fiscal year 2025, driven by growth in NGS tools and synthetic genes.
NASDAQ
Twist Bioscience saw a 28% increase in revenue in the third quarter of 2024, driven by strong growth in NGS tools and synthetic genes, but also experienced a significant increase in net losses due to impairment charges.
NASDAQ
Twist Bioscience saw a 25% increase in revenue year-over-year, reaching $75.3 million in the second quarter of 2024, driven by strong growth in NGS tools and synthetic genes.
NASDAQ
Twist Bioscience saw a 32% increase in revenue year-over-year in the first quarter of fiscal year 2024, primarily driven by growth in NGS tools, synthetic genes, and DNA libraries.